Compare SVM & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | AVDL |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | SVM | AVDL |
|---|---|---|
| Price | $11.21 | $21.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $9.00 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 5.8M | 1.6M |
| Earning Date | 02-09-2026 | 03-02-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $323,391,000.00 | $248,517,000.00 |
| Revenue This Year | $22.28 | $65.47 |
| Revenue Next Year | $32.53 | $30.88 |
| P/E Ratio | $99.10 | ★ N/A |
| Revenue Growth | 33.99 | ★ 79.88 |
| 52 Week Low | $2.93 | $6.38 |
| 52 Week High | $11.32 | $23.57 |
| Indicator | SVM | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 79.30 | 56.85 |
| Support Level | $9.70 | $21.45 |
| Resistance Level | $9.27 | $21.60 |
| Average True Range (ATR) | 0.53 | 0.08 |
| MACD | 0.17 | -0.05 |
| Stochastic Oscillator | 99.55 | 48.78 |
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.